University of Manchester news release
Researchers have used engineering biology – an emerging technology that uses nature’s own processes to manufacture everyday chemicals and materials – to dramatically simplify how lenacapavir is manufactured.
The study, published in the Journal of the American Chemical Society (JACS), describes how the research team used directed evolution to develop a bespoke aminotransferase, a type of enzyme, to significantly accelerate the manufacturing process and reduce production costs. This new biocatalytic route has the potential to improve global access to this important medicine.
Read the full news release here.
Source : University of Manchester
Related HIV and Co-Infections News
-
NIH-funded breakthrough shrinks CRISPR for precision delivery in the body
-
[Press release] US and Global Fund expand commitment to long-acting HIV prevention as country rollout of lenacapavir accelerates
-
AVAC: Abrupt shutdown of US global health supply chain raises risks for HIV, TB and malaria programs
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.